Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07011810 · ClinicalTrials.gov registry record · Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
3
Study locations

NCT07011810: Recruiting Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

NCT07011810 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 50 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07011810, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell transplants. Sclerosis, while not associated with a higher risk of death, can lead to serious disabilities. Usual treatments for cGVHD can be associated with significant side effects and unsatisfactory outcomes. A monoclonal antibody, like axatilimab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Axatilimab blocks a receptor and depletes cells that may be involved in the development of inflammation and fibrosis in cGVHD. Giving axatilimab may improve or prevent worsening of sclerosis related to cGVHD in patients after a donor stem cell transplant.

Primary Outcome

Will be defined as the proportion of patients with objective response per 2014 National Institutes of Health (NIH) skin and joint criteria.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • BIOLOGICAL Axatilimab
  • PROCEDURE Skin Biopsy
  • PROCEDURE Skin Measurement

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-06
Est. Completion 2030-02-10
Phase Phase 2
Fred Hutchinson Cancer Center

483 total trials

What NCT07011810 shows while recruiting

NCT07011810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07011810 reports a single indexed study location in Florida, Massachusetts, Washington.

Frequently Asked Questions

What is clinical trial NCT07011810 about?

NCT07011810 is a clinical study titled "Axatilimab for Sclerotic Chronic Graft-versus-Host Disease". This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell tra...

What is the current status of trial NCT07011810?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-08-06. Estimated completion is 2030-02-10.

What conditions does trial NCT07011810 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT07011810?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Axatilimab (BIOLOGICAL), Skin Biopsy (PROCEDURE), Skin Measurement (PROCEDURE).

Who is sponsoring clinical trial NCT07011810?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07011810 being conducted?

This trial has 3 study locations across Florida, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07011810's enrollment target sits among peer trials

50 12th of 30 higher than 19 of 30 other Chronic Graft Versus Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07011810

Source: ClinicalTrials.gov NCT07011810, the US trial registry maintained by the National Library of Medicine. NCT07011810 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.